Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:protein
|
| gptkbp:activities |
somatostatin receptor agonist
|
| gptkbp:affects |
insulin secretion
glucagon secretion growth hormone secretion gastrin secretion serotonin secretion |
| gptkbp:appointed_by |
intravenous infusion
subcutaneous injection |
| gptkbp:approves |
gptkb:legislation
gptkb:FDA gptkb:United_States |
| gptkbp:brand |
gptkb:Sandostatin
gptkb:Sandostatin_LAR |
| gptkbp:clinical_trial |
Phase II
Phase III Phase I |
| gptkbp:contraindication |
severe liver disease
pancreatitis hypersensitivity to octreotide |
| gptkbp:developed_by |
gptkb:Sandoz
|
| gptkbp:discovered_by |
gptkb:1980s
|
| gptkbp:formulation |
lyophilized powder
solution for injection |
| https://www.w3.org/2000/01/rdf-schema#label |
octreotide
|
| gptkbp:ingredients |
C38 H49 N5 O10 S2
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:is_available_on |
long-acting release formulation
short-acting formulation |
| gptkbp:is_used_for |
treatment of acromegaly
treatment of diarrhea associated with VI Poma treatment of neuroendocrine tumors treatment of variceal hemorrhage |
| gptkbp:lifespan |
2 hours
|
| gptkbp:marketed_as |
gptkb:Sandostatin
|
| gptkbp:related_to |
endocrine system
hormonal regulation neuroendocrine system gastrointestinal system somatostatin |
| gptkbp:rounds |
biliary
renal |
| gptkbp:side_effect |
nausea
abdominal pain diarrhea fat malabsorption gallbladder sludge |
| gptkbp:storage |
room temperature
protected from light |
| gptkbp:weight |
811.03 g/mol
|
| gptkbp:bfsParent |
gptkb:gastrinoma
gptkb:insulinomas |
| gptkbp:bfsLayer |
6
|